Blood Pressure Variability and Cardiovascular Risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)

被引:61
|
作者
Poortvliet, Rosalinde K. E. [1 ]
Ford, Ian [2 ]
Lloyd, Suzanne M. [2 ]
Sattar, Naveed [3 ]
Mooijaart, Simon P. [4 ,5 ]
de Craen, Anton J. M. [4 ]
Westendorp, Rudi G. J. [4 ,6 ]
Jukema, J. Wouter [7 ]
Packard, Christopher J. [8 ]
Gussekloo, Jacobijn [1 ]
de Ruijter, Wouter [1 ]
Stott, David J. [8 ]
机构
[1] Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, Leiden, Netherlands
[2] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland
[3] Univ Glasgow, Dept Vasc Biochem, Glasgow, Lanark, Scotland
[4] Leiden Univ, Med Ctr, Dept Gerontol & Geriatr, Leiden, Netherlands
[5] Inst Evidence Based Med Old Age, Leiden, Netherlands
[6] Netherlands Consortium Healthy Ageing, Leiden, Netherlands
[7] Leiden Univ, Dept Cardiol, Med Ctr, Leiden, Netherlands
[8] Univ Glasgow, Glasgow Royal Infirm, Fac Med, Acad Sect Geriatr Med, Glasgow G31 2ER, Lanark, Scotland
来源
PLOS ONE | 2012年 / 7卷 / 12期
基金
英国惠康基金;
关键词
SOCIETY-OF-HYPERTENSION; PROGNOSTIC-SIGNIFICANCE; GUIDELINES; INFARCTION; PREDICTOR; MORTALITY; STROKE;
D O I
10.1371/journal.pone.0052438
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Variability in blood pressure predicts cardiovascular disease in young-and middle-aged subjects, but relevant data for older individuals are sparse. We analysed data from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) study of 5804 participants aged 70-82 years with a history of, or risk factors for cardiovascular disease. Visit-to-visit variability in blood pressure (standard deviation) was determined using a minimum of five measurements over 1 year; an inception cohort of 4819 subjects had subsequent in-trial 3 years follow-up; longer-term follow-up (mean 7.1 years) was available for 1808 subjects. Higher systolic blood pressure variability independently predicted long-term follow-up vascular and total mortality (hazard ratio per 5 mmHg increase in standard deviation of systolic blood pressure = 1.2, 95% confidence interval 1.1-1.4; hazard ratio 1.1, 95% confidence interval 1.1-1.2, respectively). Variability in diastolic blood pressure associated with increased risk for coronary events (hazard ratio 1.5, 95% confidence interval 1.2-1.8 for each 5 mmHg increase), heart failure hospitalisation (hazard ratio 1.4, 95% confidence interval 1.1-1.8) and vascular (hazard ratio 1.4, 95% confidence interval 1.1-1.7) and total mortality (hazard ratio 1.3, 95% confidence interval 1.1-1.5), all in long-term follow-up. Pulse pressure variability was associated with increased stroke risk (hazard ratio 1.2, 95% confidence interval 1.0-1.4 for each 5 mmHg increase), vascular mortality (hazard ratio 1.2, 95% confidence interval 1.0-1.3) and total mortality (hazard ratio 1.1, 95% confidence interval 1.0-1.2), all in long-term follow-up. All associations were independent of respective mean blood pressure levels, age, gender, in-trial treatment group (pravastatin or placebo) and prior vascular disease and cardiovascular disease risk factors. Our observations suggest variability in diastolic blood pressure is more strongly associated with vascular or total mortality than is systolic pressure variability in older high-risk subjects.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] PROSPER (the prospective study of pravastatin in the elderly at risk)
    Shepherd, J
    [J]. AMERICAN HEART JOURNAL, 2003, 145 (03) : 559 - 561
  • [2] The design of a Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
    Shepherd, J
    Blauw, GJ
    Murphy, MB
    Cobbe, SM
    Bollen, ELEM
    Buckley, BM
    Ford, I
    Jukema, JW
    Hyland, M
    Gaw, A
    Lagaay, AM
    Perry, IJ
    Macfarlane, PW
    Meinders, AE
    Sweeney, BJ
    Packard, CJ
    Westendorp, RGJ
    Twomey, C
    Scott, DJ
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (10): : 1192 - 1197
  • [3] The prosper rationale. A prospective study of pravastatin in the elderly at risk
    Blauw, GJ
    Shepherd, J
    Murphy, M
    [J]. ATHEROSCLEROSIS, 1999, 144 : 100 - 101
  • [4] The prosper design. A prospective study of pravastatin in the elderly at risk
    Shepherd, J
    Blauw, GJ
    Murphy, M
    [J]. ATHEROSCLEROSIS, 1999, 144 : 100 - 100
  • [5] Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
    Packard, CJ
    Ford, I
    Robertson, M
    Shepherd, J
    Blauw, GJ
    Murphy, MB
    Bollen, ELEM
    Buckley, BM
    Cobbe, SM
    Gaw, A
    Hyland, M
    Jukema, JW
    Kamper, AM
    Macfarlane, PW
    Perry, IJ
    Stott, DJ
    Sweeney, BJ
    Twomey, C
    Westendorp, RGJ
    [J]. CIRCULATION, 2005, 112 (20) : 3058 - 3065
  • [6] Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
    Dilys J Freeman
    Michele Robertson
    E Ann Brown
    Ann Rumley
    Edward S Tobias
    Marijke Frölich
    P Eline Slagboom
    J Wouter Jukema
    Anton JM de Craen
    Naveed Sattar
    Ian Ford
    Allan Gaw
    Ian A Greer
    Gordon DO Lowe
    David J Stott
    [J]. BMC Geriatrics, 11
  • [7] Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
    Freeman, Dilys J.
    Robertson, Michele
    Brown, E. Ann
    Rumley, Ann
    Tobias, Edward S.
    Frolich, Marijke
    Slagboom, P. Eline
    Jukema, J. Wouter
    de Craen, Anton J. M.
    Sattar, Naveed
    Ford, Ian
    Gaw, Allan
    Greer, Ian A.
    Lowe, Gordon D. O.
    Stott, David J.
    [J]. BMC GERIATRICS, 2011, 11
  • [8] A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics
    Ian Ford
    Gerard Jan Blauw
    Michael B Murphy
    James Shepherd
    Stuart M Cobbe
    Edward LEM Bollen
    Brendan M Buckley
    J Wouter Jukema
    Michael Hyland
    Allan Gaw
    A Margot Lagaay
    Ivan J Perry
    Peter Macfarlane
    John Norrie
    A Edo Meinders
    Brian J Sweeney
    Chris J Packard
    Rudi GJ Westendorp
    Cillian Twomey
    David J Stott
    [J]. Current Controlled Trials in Cardiovascular Medicine, 2002, 3
  • [9] A prospective study of pravastatin in the elderly at risk (PROSPER): Screening experience and baseline characteristics
    Ford, I
    Blauw, GJ
    Murphy, MB
    Shepherd, J
    Cobbe, SM
    Bollen, ELEM
    Buckley, BM
    Jukema, JW
    Hyland, M
    Gaw, A
    Lagaay, AM
    Perry, IJ
    Macfarlane, PW
    Norrie, J
    Meinders, AE
    Sweeney, BJ
    Packard, CJ
    Westendorp, RGJ
    Twomey, C
    Stott, DJ
    [J]. CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2002, 3 (1):
  • [10] Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the prospective study of pravastatin in the elderly at risk (PROSPER)
    Gaw, A
    Murray, HM
    Brown, EA
    [J]. ATHEROSCLEROSIS, 2005, 180 (02) : 381 - 388